Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

CMC and Bioprocess Blog

Execution-focused articles on CMC strategy, bioprocess scale-up, tech transfer, CDMO selection, and GMP readiness for process development scientists and manufacturing leaders scaling biologics into regulatory-ready therapies.

Uncategorized

Today we’re diving into something that could literally save your company from becoming another biotech statistic.

Bioprocessing

What happens when the charging elephant of biotech—antibody-drug conjugates (ADCs)—meets the organizational complexity of a 300-strong analytical powerhouse?

Bioprocessing

Antibody-drug conjugates (ADCs) are generating serious buzz in biotech corridors, offering a precision-guided missile against cancer while minimizing collateral damage.

Bioprocessing

A common misconception among many researchers and biotech startup founders is that bioprocess development is straightforward.

Innovation

The world of medicine stands on the precipice of a new era.

Biotech Success

What’s the single most formidable hurdle for a promising biotech breakthrough? It’s crafting a robust CMC (Chemistry, Manufacturing, and Controls) strategy.

Bioprocessing

Biologics development is full of hidden pitfalls, from selecting the right cell line to navigating analytical assessments that can make or break a therapy’s success.

Bioprocessing

How can small biotech companies navigate increasing molecular complexity, tight budgets, and the ever-present pressure to accelerate timelines while ensuring long-term process success?

Bioprocessing

Is your process model gathering dust while real-world decisions march on without it?

Bioprocessing

Bioprocess development lies at the heart of modern biotechnology, turning innovative molecules into life-changing therapies.

Bioprocessing

Bioreactor scale-up failures are still one of the top reasons promising cell therapies never reach the clinic. Traditional “power per volume” scale-up is often just a best guess—putting product quality and timelines at risk.

Bioprocessing

Can computational fluid dynamics (CFD) join the ranks of everyday tools in bioprocess engineering—right alongside spreadsheets and pH meters?

Data & Analytics

For years, protein engineering has struggled with a fundamental bottleneck: machine learning models, powerful as they are, have been starved of meaningful data.

Data & Analytics

Antibody therapeutics have transformed modern medicine, but for many scientists, developing new candidates still feels like searching for a needle in a haystack—a slow, expensive, and unpredictable process.

Data & Analytics

AI won’t replace your bioprocessing team—but it will make them more indispensable than ever.

Data & Analytics

What if the secret to reliable, real-time bioprocessing isn’t buried in another wet-lab experiment, but hiding inside your data—waiting for the right digital ally?

Data & Analytics

If you could run an experiment in your computer instead of the lab—and it actually gave you answers worth acting on—would you try it?

Data & Analytics

Imagine trimming years off biologics development—and catching problematic formulations long before the first pipette is even picked up.

Biotech Success

How do you know when your biotech startup is ready to sell—before the product is “perfect”?

Biotech Success

Most bioprocess innovation is dismissed as a “fool’s game”—until the skeptics are proven wrong.

Biotech Success

What happens when the solution to America’s insulin crisis isn’t a new molecule or fancy delivery device—but a new way of thinking about biotech itself?

Biotech Success

What if affordable insulin isn’t a scientific hurdle—but a financial and distribution puzzle no one’s been motivated to solve?

Biotech Success

Securing capital for biotech innovation has never been more challenging—or more crucial.

Biotech Success

Strong science alone won’t get your biotech startup funded—investors are sizing up much more than just your molecule.

Innovation

Bioreactors have relied on impellers for decades, yet these mechanical mixers create shear forces that damage fragile cells such as induced pluripotent stem cells, natural killer cells, and dinoflagellates.

Innovation

Biopharmaceutical production has undergone remarkable transformations in recent decades, driven by the growing complexity of therapeutic molecules and the demand for faster, more efficient, and more flexible manufacturing strategies.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.

No spam. Unsubscribe anytime.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.


No spam. Unsubscribe anytime.